Article
Clopidogrel in noncarriers of CYP2C19 loss-of-function alleles versus ticagrelor in elderly patients with acute coronary syndrome: A pre-specified sub analysis from the POPular Genetics and POPular Age trials CYP2C19 alleles in elderly patients.
International journal of cardiology - 1 Jul 2021
Claassens Daniel M F, Gimbel Marieke E, Bergmeijer Thomas O, Vos Gerrit J A, Hermanides Renicus S, van der Harst Pim, Barbato Emanuele, Morisco Carmine, Tjon Joe Gin Richard M, de Vrey Evelyn A, Heestermans Ton A C M, Jukema J Wouter, von Birgelen Clemens, Waalewijn Reinier A, Hofma Sjoerd H, den Hartog Frank R, Voskuil Michiel, Van't Hof Arnoud W J, Asselbergs Folkert W, Mosterd A, Herrman Jean-Paul R, Dewilde Willem, Mahmoodi Bakhtawar K, Deneer Vera H M, Ten Berg Jurriën M
Abstract excerpt
BACKGROUND: Patients with acute coronary syndrome (ACS) who are carrying CYP2C19 loss-of-function alleles derive less benefit from clopidogrel treatment. Despite this, in elderly patients, clopidogrel might be preferred over more potent P2Y12 inhibitors due to a lower bleeding risk. Whether CYP2C19 genotype-guided antiplatelet treatment in the elderly could be of benefit has not been studied specifically....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.